CSIMarket
 
Oric Pharmaceuticals Inc   (ORIC)
Other Ticker:  
 
 


 
 ORIC $13.7500 $0.2900 2.15%

 Volume (M): 726   Open : 13.52    52 Wk Avg :  8.18

 
 ORIC $13.7500 $0.2900 2.15%

 Volume (M): 726   Open : 13.52    52 Wk Avg :  8.18




ORIC Today's High: $14.07 ORIC Shares One Week Perf: -5.76 %
ORIC Today's Low: $ 13.19 ORIC Shares 30 Day Performance: 14.77 %
Number of ORIC Shares Traded (M): 726 ORIC Share Price 52 Wk High: $ 16.65
Value of ORIC's Shares Traded (M$): $ 9,976 ORIC Share Price 52 Wk Avg: $8.18
Share Price at the Open: $13.52 ORIC's Share Price 52 Wk Low: $4.89



  News about Oric Pharmaceuticals Inc's Stock Splits and Dividends

ORIC Pharmaceuticals Grants Inducement Options and Restricted Stock Units to New Employees, Demonstrating Confidence in Company's Growth Potential



ORIC Pharmaceuticals, a leading clinical-stage oncology company, made an exciting announcement today regarding the granting of inducement options and restricted stock units to two new non-executive employees. The grant serves as a testament to the company's commitment to attracting top talent and further developing treatments that target therapeutic resistance in the field of oncology. This article will outline the details of the press release and assess the potential impact of these inducement grants on the company's shares.
Facts:
On February 1, 2024, ORIC Pharmaceuticals granted a total of 12,500 non-qualified stock options and 2,100 restricted stock units to two new non-executive employees who recently joined the company in January 2024. These inducement grants were made under Nasdaq Listing Rule 5635(c)(4), reflecting ORIC's efforts to enhance its workforce and strengthen its position in the highly competitive oncology industry.

Fueling Growth: ORIC Pharmaceuticals' Inducement Grants Drive Positive Momentum in Shares



ORIC Pharmaceuticals, a clinical stage oncology company, has recently granted inducement incentives to a non-executive employee, showcasing their commitment to talent acquisition and development. This press release sheds light on the details of the grant and its impact on the company's shares and overall performance.

1. Overview of the Inducement Grants:
ORIC Pharmaceuticals granted a total of 14,800 non-qualified stock options and 2,480 restricted stock units to a new non-executive employee on November 1, 2023. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), allowing the company to attract and retain valuable talent in their ongoing pursuit of developing innovative treatments for therapeutic resistance in oncology.

ORIC Pharmaceuticals Bolsters Workforce with Inducement Grants for New Employees, Reinforcing Commitment to Oncology Breakthroughs

ORIC Pharmaceuticals Grants Inducement Options and Restricted Stock Units to New Employees
ORIC Pharmaceuticals, a clinical stage oncology company dedicated to developing innovative treatments for therapeutic resistance, has recently announced the issuance of inducement grants under Nasdaq Listing Rule 5635(c)(4). On October 2, 2023, ORIC granted a total of 72,120 non-qualified stock options and 12,040 restricted stock units to four new non-executive employees who joined the company in September 2023.
The inducement grants are part of ORIC's ongoing efforts to attract and retain top talent in the competitive field of oncology research. By offering an incentive package that includes stock options and restricted stock units, ORIC aims to align employee interests with the long-term growth and success of the company. These equity-based incentives not only encourage employees to contribute their expertise and drive to ORIC's mission but also reward them for their dedication and commitment.





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com